Sanofi Ranks First in 2026 CNS Summit Digital Innovation Index

Sanofi ranked first in the 2026 CNS Summit Digital Innovation Index, placing in the top three in all three categories, the index's organizers announced on November 4, 2026. The rankings were revealed on the CNS Summit 2026 main stage at Encore Boston Harbor, PR Newswire reported.

Sanofi's Top Ranking and Category Leaders

The Index, now in its 11th year, ranks the top 30 pharmaceutical companies on digital innovation, using publicly reported initiatives and investments from July 2025 through July 2026. It was developed in collaboration with IDEA Pharma, a division of SAI MedPartners. The 2026 top 10 are Sanofi, Eli Lilly, AstraZeneca, Chugai, Roche, Bristol Myers Squibb, Novo Nordisk, Johnson & Johnson, Boehringer Ingelheim and Merck KGaA. Category leaders were Roche in commercial, Novo Nordisk in clinical development and Recursion in research.

"Ranking first in the Pharmaceutical Digital Innovation Index reflects a shift we are proud of: digital and AI at Sanofi are now a connected system spanning research, clinical development and commercial operations," said Emmanuel Frenehard, Chief Digital Officer, Sanofi. Dr. Alexander Gray, IDEA Pharma's Chief Medical Officer and SVP of Consulting, said this year's leaders "demonstrate the value of connecting innovation across research, clinical development and commercial operations, setting a new benchmark for the industry."

Sanofi's Digital and AI Investments

Sanofi is a global biopharmaceutical company that develops and commercializes prescription medicines, vaccines and consumer healthcare products across immunology, neurology, oncology, rare diseases and vaccines, serving patients and healthcare systems in more than 100 countries, according to akta.pro company records. The same records show Sanofi entered a multi-year Owkin partnership in June 2026 with a five-year K Pro AI platform license, building on a $180 million equity stake and a €90 million prior collaboration to deploy agentic AI across R&D workflows. In June 2026 Sanofi also signed a memorandum of understanding with the Abu Dhabi Department of Health at BIO 2026 to establish a Vaccine Innovation Centre in the United Arab Emirates.

Earlier Sanofi Moves in 2026

Sanofi appointed Paulo Fontoura as Executive Vice President and Global Head of R&D Pharma effective September 1, 2026, recruiting him from Xaira Therapeutics, where he was chief medical officer, and replacing Houman Ashrafian, according to company records. Geetanjali Ashok was promoted to Marketing Transformation & AI Enablement Lead at Sanofi, effective September 1, based in Paris, exchange4media reported. On November 3, 2026, Nurix Therapeutics said Sanofi will discontinue the Phase 1 trial of oral STAT6 degrader SAR448272 and terminate the program, TradingView reported.

What Comes Next for Sanofi

The full 2026 rankings and white paper are available at cnssummit.org/innovation-index and ideapharma.com/pii/report/digital, the organizers said.